(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
India's top court hears challenges to ruling on women's entry into temple - 2'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war
- 3Dave Coulier shares new cancer diagnosis 1 year after revealing previous diagnosis
- 4Israel strikes Beirut amid rocket fire from Hezbollah and Iran
- 5Figure out how to Guarantee Your Dental Embeds Endure forever
- Massive supernova explosion may have created a binary black hole
- The race to mine the moon is on – and it urgently needs some clear international rules
- IDF destroys Hezbollah rocket launcher used in large rocket salvo towards Haifa, Galilee
- Creative Do-It-Yourself Ventures for Each Expertise Level
- Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- The Best Games On the planet
- Vote in favor of your Favored kind of craftsmanship
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
